Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 11 of the 68 sources its claims cite were checked for support.

KRAS, a New Target for Precision Medicine in Colorectal Cancer?

Open access

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with significant public health concerns. This review examines the landscape of KRAS inhibition in colorectal cancer (CRC), focusing on recent advances in therapeutic strategies targeting this oncogene. Historically deemed undruggable due to its complex structure and essential role in tumorigenesis, KRAS mutations are prevalent in CRC and are associated with poor prognosis. However, breakthroughs in drug development have led to the emergence of KRAS inhibitors as promising treatment options. This review discusses various classes of KRAS inhibitors, including covalent and non-covalent inhibitors, as well as combination therapies aimed at enhancing efficacy and overcoming resistance mechanisms. It highlights recent clinical trials evaluating the efficacy of KRAS inhibitors either as monotherapy or in combination with other agents, such as anti-EGFR antibodies. Despite challenges such as resistance mechanisms and tumor heterogeneity, the development of KRAS inhibitors represents a significant advance in CRC treatment and holds promise for improving patient outcomes in the future.

Overview

CoChat Summary

TL;DR

This review summarizes KRAS inhibition strategies in colorectal cancer, including covalent and non-covalent mutation-specific inhibitors, pan-KRAS inhibitors, indirect inhibitors, and combination approaches to overcome resistance. It reports early clinical efficacy for KRAS G12C inhibitors alone and with anti-EGFR antibodies, while emphasizing remaining resistance and the need for further trials.

Key findings

  • KRAS mutations occur in approximately 40–50% of colorectal cancers; common codon 12 mutations G12D and G12V account for about 28% and 19% of KRAS mutations in CRC, respectively, and G13D for 17%, while codon 61 mutations account for approximately 5–10%.
  • In KRAS G12C-mutant CRC, adagrasib monotherapy produced an objective response rate of 23%, disease control rate of 86%, median progression-free survival of 5.6 months, median overall survival of 19.8 months, and grade 3–4 toxicities in 34% (n = 43); sotorasib monotherapy produced an objective response rate of 9.7%, disease control rate of 82.3%, median progression-free survival of 4.0 months, median overall survival of 10.6 months, and grade 3–4 toxicities in 10% (n = 62).
  • Combining KRAS G12C inhibitors with anti-EGFR antibodies increased activity: sotorasib plus panitumumab had an objective response rate of 30% versus 10% for sotorasib monotherapy, and the phase III combination arm had progression-free survival of 5.6 months; adagrasib plus cetuximab was associated with a 46% response rate, median response duration of 7.6 months, and median progression-free survival of 6.9 months.
  • Preclinically, MRTX1133 showed approximately 700-fold higher selectivity for KRAS G12D over wild-type KRAS and induced tumor regression of 30% or more in 11 of 25 KRAS G12D mutant models, including 8 of 11 pancreatic cancer models.

Methods

  • Narrative review synthesizing preclinical and clinical studies on KRAS signaling and KRAS-targeted therapies in colorectal cancer; no systematic review search strategy or meta-analysis is described.
  • Data include published literature, early-phase through phase III clinical trials, and tables of safety/efficacy for KRAS G12C inhibitors in CRC and ongoing clinical trials.
  • Main analysis is a qualitative synthesis of mechanisms, resistance pathways, drug classes, and combination strategies.

Limitations

  • The paper states that challenges remain in addressing resistance mechanisms and optimizing therapeutic regimens to maximize efficacy while minimizing toxicity; further clinical studies are warranted to validate emerging therapies, explore optimal combinations, and identify predictive biomarkers.
  • Evident from the text: as a narrative review, it does not report a systematic search, inclusion criteria, or risk-of-bias assessment; many cited data are from early-phase trials or preclinical models, and CRC-specific data are limited for some strategies such as pan-KRAS inhibitors, vaccines, and CAR-T cells.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers16203455

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 KRAS pathway (created with biorender).
Figure 1 KRAS pathway (created with biorender).CC BY · PubMed Central
Figure 2 KRAS mutations prevalence in solid tumors and CRC. (A) Percentage of KRAS alterations (tumors with prevalence > 10%), according to the GENIE cohort v13.0-public (red: colorectum) [4]. (B) KRAS mutation prevalence in CRC (from [1]).
Figure 2 KRAS mutations prevalence in solid tumors and CRC. (A) Percentage of KRAS alterations (tumors with prevalence > 10%), according to the GENIE cohort v13.0-public (red: colorectum) [4]. (B) KRAS mutation prevalence in CRC (from [1]).CC BY · PubMed Central
Figure 3 Mechanisms of bypassing KRAS inhibitors through the activation of wild-type (WT) forms of RAS (NRAS and HRAS) [29,31] (biorender).
Figure 3 Mechanisms of bypassing KRAS inhibitors through the activation of wild-type (WT) forms of RAS (NRAS and HRAS) [29,31] (biorender).CC BY · PubMed Central
Figure 4 Therapeutic approaches to target KRAS.
Figure 4 Therapeutic approaches to target KRAS.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 0 Not valid · 43 Not checked · 14 Own results and interpretations

25 more claims

Create a free account to see all 63 claims and to verify the 57 references still open.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 64 references

Cited by

See all 12

Metadata

Authors
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., Mathieu, J. R. R., Jaulin, F., Hollebecque, A., & Ducreux, M.
Affiliations
  • Inserm (FR)
  • Institut Gustave Roussy (FR)
  • Université Paris-Saclay (FR)
Corresponding author
Boilève, Alice
Venue
Cancers
Publisher
MDPI AG
Published
2024-10-12
Volume
16
Issue
20
Pages
3455
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4403400820
Cited by
11
References
64
Citations by year
2026: 4 · 2025: 6 · 2024: 1
FWCI
0.59
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Research Agency (ANR-21-RHUS-0003)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
KRAS, colorectal cancer, KRAS inhibitors, precision medicine, covalent inhibitors, non-covalent inhibitors, combination therapy, anti-EGFR monoclonal antibody, drug resistance, tumor heterogeneity, KRAS mutation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: KRAS, a New Target for Precision Medicine in Colorectal Cancer? https://app.cochat.ai/papers/10.3390/cancers16203455
The paper
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., Mathieu, J. R. R., Jaulin, F., Hollebecque, A., & Ducreux, M. (2024). KRAS, a New Target for Precision Medicine in Colorectal Cancer? Cancers. https://doi.org/10.3390/cancers16203455

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.